CU Research Helps Ease Barriers to CAR-T Therapy for Lymphoma Patients

A study led by Manali Kamdar, MD, at the University of Colorado Cancer Center supported an FDA rule change cutting patient monitoring time after CAR-T therapy from four weeks to two. The shift is expected to expand access for people with lymphoma who previously faced major logistical and financial hurdles.